A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis

Inclusion criteria

• AD patients diagnosed in accordance with the consensus criteria of the American Academy of Dermatology (2014) had a history of AD or eczema diagnosis of ≥1 year
• The patient's response to topical medication treatment is insufficient, or it is medically inappropriate to use topical medication for treatment
• The subjects and their partners agreed to take effective contraceptive measures from signing the Informed Consent Form (ICF) until 6 months after the end of treatment, and had no plans for childbirth, sperm donation or egg donation

Exclusion criteria

• The subject currently has a diagnosis of other active skin diseases (such as psoriasis or lupus erythematosus) that may affect the evaluation of AD
• Patients with eye diseases that the researchers judged as unsuitable for inclusion
• Patients with malignant tumors within 5 years
• There is evidence of active tuberculosis, or there has been evidence of active tuberculosis before and no appropriate documented treatment has been received
• Confirm active parasitic infection
• Those with active hepatitis, or positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb), or positive for hepatitis C virus (HCV) antibody, or positive for HIV antibody, or positive for (TP-Ab)
• Women who are breastfeeding or pregnant, or women planning to become pregnant or breastfeed during the study period
• Those who the researchers consider to have other circumstances that make them unsuitable to participate in the study